Evidence map›Paper›PMID 33750045›Full record

ArticleMolecular genetics & genomic medicine2021

Novel frameshift mutation in PURA gene causes severe encephalopathy of unclear cause.

Lucía Spangenberg, Rosario Guecaimburú, Alejandra Tapié, Susana Vivas, Soledad Rodríguez, Martín Graña, Hugo Naya, Víctor Raggio

Open access · goldAbstract readCase Reports
In one paragraph

Article in Molecular genetics & genomic medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Heterozygous c.175C>T variant inClinical case reports · 2023
    Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Lucía SpangenbergUnidad de Bioinformática, Institut Pasteur de Montevideo, Montevideo, Uruguay.ORCID 0000-0001-5124-9250
Rosario GuecaimburúEquipo de Enfermedades Raras, CRENADECER, BPS, Montevideo, Uruguay.
Alejandra TapiéDepartamento de Genética, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay.
Susana VivasEquipo de Enfermedades Raras, CRENADECER, BPS, Montevideo, Uruguay.
Soledad RodríguezDepartamento de Genética, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay.
Martín GrañaUnidad de Bioinformática, Institut Pasteur de Montevideo, Montevideo, Uruguay.ORCID 0000-0003-1182-8236
Hugo NayaUnidad de Bioinformática, Institut Pasteur de Montevideo, Montevideo, Uruguay.ORCID 0000-0001-6982-4399
Víctor RaggioDepartamento de Genética, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay.
Universidad de la República de Uruguay · UYInstitut Pasteur de Montevideo · UYUniversidad de Montevideo · UY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe etiology of many genetic diseases is challenging. This is especially true for developmental disorders of the central nervous system, since several genes can be involved. Many of such pathologies are considered rare diseases, since they affect less than 1 in 2000 people. Due to their low frequency, they present several difficulties for patients, from the delay in the diagnosis to the lack of treatments. Next-generation sequencing techniques have improved the search for diagnosis in several pathologies. Many studies have shown that the use of whole-exome/genome sequencing in rare Mendelian diseases has a diagnostic yield between 30% and 50% depending on the disease.

methodsHere, we present the case of an undiagnosed 6-year-old boy with severe encephalopathy of unclear cause, whose etiological diagnosis was achieved by whole-genome sequencing.

resultsWe found a novel variant that has not been previously reported in patients nor it has been described in GnomAD. Segregation analysis supports a de novo mutation, since it is not present in healthy parents. The change is predicted to be harmful to protein function, since it falls in the first quarter of the protein producing an altered reading frame and generating a premature stop codon. Additionally, the variant is classified as pathogenic according to ACMG criteria (PVS1, PM2, and PP3). Furthermore, there are several reported frameshift mutations in nearby codons as well as nonsense mutations that are predicted as pathogenic in other studies.

conclusionWe found a novel de novo frameshift mutation in the PURA gene (MIM number 600473), c.151_161del, with sufficient evidence of its pathogenicity.

Indexed as

Frameshift MutationPhenotypeBrain DiseasesChildDNA-Binding ProteinsHumansMaleTranscription FactorsDNA-Binding ProteinsPURA protein, humanTranscription Factors

Identifiers

PMID33750045
PMCPMC8172205
OpenAlexW3138302723

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.